Talphera (NASDAQ:TLPH) Now Covered by Analysts at Rodman & Renshaw

Research analysts at Rodman & Renshaw began coverage on shares of Talphera (NASDAQ:TLPH) in a research report issued to clients and investors on Tuesday, MarketBeat reports. The brokerage set a “buy” rating and a $4.00 price target on the stock. Rodman & Renshaw’s price objective indicates a potential upside of 470.61% from the stock’s previous close.

Several other analysts have also recently issued reports on the stock. Maxim Group upgraded shares of Talphera to a “strong-buy” rating in a research note on Friday, November 8th. HC Wainwright reiterated a “buy” rating and set a $6.00 price target on shares of Talphera in a research report on Tuesday, January 21st.

Talphera Price Performance

NASDAQ:TLPH opened at $0.70 on Tuesday. Talphera has a 1 year low of $0.50 and a 1 year high of $1.61. The stock’s fifty day moving average price is $0.65 and its two-hundred day moving average price is $0.81. The company has a market cap of $11.94 million, a P/E ratio of -1.02 and a beta of 0.28.

Institutional Trading of Talphera

A hedge fund recently bought a new stake in Talphera stock. Nantahala Capital Management LLC bought a new stake in shares of Talphera, Inc. (NASDAQ:TLPH) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 1,992,519 shares of the company’s stock, valued at approximately $1,773,000. Nantahala Capital Management LLC owned 11.73% of Talphera at the end of the most recent reporting period. Institutional investors own 37.67% of the company’s stock.

Talphera Company Profile

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit.